Author:
Joseph Nisha S.,Lonial Sagar
Reference5 articles.
1. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma;Hungria;N. Engl. J. Med.,2024
2. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma;Dimopoulos;N. Engl. J. Med.,2024
3. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study;Dimopoulos;Lancet. Haematol.,2023
4. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma;Rodriguez-Otero;N. Engl. J. Med.,2023
5. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma;San-Miguel;N. Engl. J. Med.,2023